Chance Pharma, a Hangzhou, China-based clinical-stage biotechnology company, raised an undisclosed amount in new funding.
Backers included Heda Health Fund and Qihang Venture Capital.
The company intends to use the funds to support the advancement of Phase III clinical trials for CXG87, an improved formulation of budesonide/formoterol inhalation powder, as well as the development of new inhalation powder formulations.
Led by CEO and Founder Dr. Donghao Chen, Chance Pharmaceuticals is a clinical-stage biotechnology company dedicated to the research and development of innovative dry powder inhalation (DPI) therapies. Its pipeline is supported by two core technology platforms: milling and mixing, and spray drying. Its proprietary spray drying platform enables the transformation of biological macromolecules, low-activity drugs, and deep lung/systemic delivery drugs into highly efficient dry powder inhalation formulations. The company operates production facilities compliant with FDA and EMA quality standards, underscoring its strong capabilities in both R&D and manufacturing.
Through independent innovation and strategic partnerships, it is advancing a diverse portfolio of programs targeting respiratory diseases, central nervous system (CNS) disorders, and fibrotic diseases.
FinSMEs
17/03/2025